Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Daratumumab (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 31 May 2025 Planned End Date changed from 1 Nov 2025 to 1 May 2026.
- 30 Dec 2024 Planned End Date changed from 1 Nov 2024 to 1 Nov 2025.
- 10 Mar 2023 Planned primary completion date changed from 1 Nov 2023 to 8 Nov 2023.